Fagron Concepts

Nourisil™ MD contains a unique blend of silicones and Vitamin E to improve the appearance of scars and maintain the skin’s moisture balance.
SyrSpend® SF PH4 is Fagron's innovative oral suspension vehicle, compatible with a wide range of API's and superior to traditional suspension vehicles
An innovative solution for dermatological care.

Fagron product Nourisil MD approved for NHS drug tariff

Tue, 19/12/2017

A Fagron product has been approved for the NHS drug tariff in England and Wales. Nourisil MD, a silicone scar gel, will be available for prescription from February 2018.

The product, which is a Class 1 Medical Device, contains a unique blend of 5 silicones and Vitamin E. Silicone is known as the ‘gold standard’ when treating hypertrophic and keloid scars resulting from surgery, wounds, trauma and burns.

Due to its formulation and matte finish, Nourisil MD is well regarded by health care professionals as it dries quickly which allows patients to add make up or sun block to the affected area.

Fagron UK General Manager Peter Batty said:

“We are delighted to have been successful in our application to have Nourisil MD listed on the NHS drug tariff. The feedback we’ve had from health care professionals, particularly in the area of burns, has been excellent and we’re pleased to offer a new alternative to specialists in this area.

An important benefit of the product is that it dries incredibly quickly when compared to other scar treatment products which we believe is important for patients.”

Nourisil MD arrives in a 30g airless dispenser and is manufactured in Holland.

For further information about Nourisil MD, contact Fagron UK Marketing and Innovation Manager via dan.barton@fagron.co.uk